Skip to main content

Table 1 Patient demographics, pathology, and imaging

From: I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma

Patient no. Age/sex Race Child-Pugh score Etiology TNM AJCC path grading I-124 Czb baseline 10 mg I-124 Czb second injection (mg/kg) I-124 Czb third injection 10 mg Day between IHC sample and I-124 Czb second injection IHC H membrane IHC H cytoplasmic SUVmax tumor of biopsied lesion
1 63/M White A None IIIB Poorly differentiated Yes 5 ND 41 4 7 7
2 71/M White A None IV Cannot be assessed Yes ND ND 18 155 84 30.9
4 67/M White B None IV Cannot be assessed Yes ND ND 34 145 15 7.3
5 69/F Asian A None IIIC Well differentiated Yes 5 ND 46 30 25 5.8
6 64/M White A None IIIB Cannot be assessed Yes ND ND 11 0 15 NA
7 82/M White A None IIIB Moderately differentiated Yes 5 Yes 46 40 13 6.7
8 62/M White A HepC IV Cannot be assessed Yes ND ND 21 4 6 6.8
9 81/M Asian A HepB N/A Well differentiated Yes 2.5 Yes 38 5 85 8.1
10 58 M Asian A HepB I Undifferentiated Yes ND ND 10 165 150 12.8
11 68/F A/A A HepC IV Cannot be assessed Yes ND ND 14 1 25 4.9
13 58/M A/A A HepC, Alcoholic IIIA Poorly differentiated Yes ND ND ND ND ND ND
14 60/M White A HepC IV Cannot be assessed Yes 2.5 Yes 27 2 62 8.4
16 59/M White A Alcoholic IV Moderately differentiated Yes 2.5 ND ND ND ND ND
17 50/M White A HepB IV Well differentiated Yes 2.5 ND ND ND ND ND
  1. Abbreviations: path pathology, Czb codrituzumab, A/A African-American, TNM tumor, node, metastasis staging system, AJCC American Joint Committee on Cancer, IHC immunohistochemistry, ND not done